Evidence map›Paper›PMID 36747562›Full record

ArticleHeliyon2023

Estrogen receptor targeting with genistein radiolabeled Technetium-99

Danni Ramdhani, Nita Listiani, Maula Eka Sriyani, Eva Maria W, Hiroshi Watabe, Resmi Mustarichie, Sri Agung Fitri Kusuma, Regaputra S Janitra

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Danni RamdhaniDepartment of Pharmaceutical Analysis and Medicinal Chemistry, Padjadjaran University, Sumedang, West Java, 45363, Indonesia.
Nita ListianiDepartment of Pharmaceutical Analysis and Medicinal Chemistry, Padjadjaran University, Sumedang, West Java, 45363, Indonesia.
Maula Eka SriyaniApplied Nuclear Science and Technology Center (PSTNT), National Nuclear Energy Agency of Indonesia (BATAN), Bandung, West Java 40116, Indonesia.
Eva Maria WApplied Nuclear Science and Technology Center (PSTNT), National Nuclear Energy Agency of Indonesia (BATAN), Bandung, West Java 40116, Indonesia.
Hiroshi WatabeDivision of Radiation Protection and Safety Control, Cyclotron and Radioisotope Center (CYRIC), Tohoku University, Sendai 980-0845, Japan.
Resmi MustarichieDepartment of Pharmaceutical Analysis and Medicinal Chemistry, Padjadjaran University, Sumedang, West Java, 45363, Indonesia.
Sri Agung Fitri KusumaDepartment of Biology Pharmacy, Faculty of Pharmacy, Padjadjaran University, Sumedang, West Java, 45363, Indonesia.
Regaputra S JanitraBiotechnology Master Program, Faculty of Postgraduate, Padjadjaran University, Bandung 40132, Indonesia.
Padjadjaran University · IDNational Nuclear Energy Agency of Indonesia · IDTohoku University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Genistein is an isoflavone molecule with a high affinity for estrogen receptors (ER), which could lead to the mechanism of selective estrogen receptor modulators (SERMs) in breast cancer. Genistein labeling with technetium-99 Methods: The genistein was directly labeled with Results: The radiochemical purity of [ Conclusions: As a result, [

Indexed as

Breast cancerDensity functional theoryEstrogen receptors βGenisteinPhysicochemical propertiesTechnetium-99 mThermodynamic stability

Identifiers

PMID36747562
PMCPMC9898673
OpenAlexW4317677557

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.